Skip to main content

Advertisement

Table 1 Clinical, treatment and dosimetric parameters

From: Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

  Median (range) Count (%)
Continuous variables   
  Age (years) 70 (54–86)  
  Initial PSA (ng/mL) 11.95 (3.7–48.0)  
  Positive biopsy rate (%) 33.0 (13.0–100)  
  Prostate D90 (Gy) 124.8 (100.0–206.5)  
  BED (Gy2) 213.5 (178.5–245.5)  
Categorical variables   
  PSA level in ng/mL   
   <10   86 (41.7%)
   10-20   39 (19.0%)
   ≥ 20   81 (39.3%)
  Gleason score   
   5-6   26 (12.6%)
   7   54 (26.2%)
   8-10   126 (61.2%)
  Clinical T stage   
   T1-T2a   142 (69.0%)
   T2b-T2c   46 (22.4%)
   T3a   18 (8.6%)
  No. of high-risk features   
   1   186 (90.3%)
   2   19 (9.2%)
   3   1 (0.5%)
  Neoadjuvant ADT   
   Yes   101 (49.0%)
  1. Abbreviations: PSA = prostate specific antigen; D90 = the minimal dose received by 90% of the prostate; BED = biologically effective dose; ADT = androgen deprivation therapy.